What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
作者信息
Riley S A
机构信息
Department of Gastroenterology, Northern General Hospital, Sheffield, UK.
出版信息
Gut. 1998 Jun;42(6):761-3. doi: 10.1136/gut.42.6.761.
Abstract
摘要
相似文献
1
What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?溃疡性结肠炎中5-氨基水杨酸（美沙拉嗪）的剂量是多少？
Gut. 1998 Jun;42(6):761-3. doi: 10.1136/gut.42.6.761.
2
A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis.一种新型美沙拉嗪泡沫灌肠剂（Claversal Foam）与标准液体灌肠剂治疗活动性远端溃疡性结肠炎患者的比较。
Aliment Pharmacol Ther. 2002 Mar;16(3):415-23. doi: 10.1046/j.1365-2036.2002.01199.x.
3
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.与美沙拉嗪灌肠剂相比，两种剂量配方的阿利卡福森灌肠剂治疗轻至中度左侧溃疡性结肠炎的安全性和有效性：一项随机、双盲、活性对照试验。
Aliment Pharmacol Ther. 2006 May 15;23(10):1403-13. doi: 10.1111/j.1365-2036.2006.02837.x.
4
Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.美沙拉嗪在溃疡性结肠炎及其并发症的急性和长期治疗中的作用。
Scand J Gastroenterol Suppl. 2002(236):42-7. doi: 10.1080/003655202320621445.
5
Encapsulated mesalamine granules (Apriso) for ulcerative colitis.用于溃疡性结肠炎的肠溶型美沙拉嗪颗粒（Apriso）
Med Lett Drugs Ther. 2009 May 18;51(1312):38-9.
6
Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.临床试验：一项随机对照临床研究，比较低剂量与高剂量美沙拉嗪泡沫剂在活动性远端溃疡性结肠炎中的疗效和安全性。
Aliment Pharmacol Ther. 2007 Nov 1;26(9):1237-49. doi: 10.1111/j.1365-2036.2007.03468.x.
7
Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study.美沙拉嗪泡沫灌肠剂（莎尔福泡沫剂）治疗远端溃疡性结肠炎的疗效和耐受性：一项双盲、随机、安慰剂对照研究。
Aliment Pharmacol Ther. 2000 Sep;14(9):1191-8. doi: 10.1046/j.1365-2036.2000.00784.x.
8
[Mesalazine old and new].[美沙拉嗪的新旧情况]
Gastroenterol Hepatol. 2011 Dec;34 Suppl 3:25-9. doi: 10.1016/S0210-5705(11)70095-4. Epub 2014 Oct 30.
9
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.对于广泛性轻度/中度活动性溃疡性结肠炎患者，口服与灌肠联合使用颇得斯安（美沙拉嗪）治疗优于单纯口服治疗：一项随机、双盲、安慰剂对照研究。
Gut. 2005 Jul;54(7):960-5. doi: 10.1136/gut.2004.060103.
10
Treatment of distal ulcerative colitis: now the patients have the choice.
Ital J Gastroenterol Hepatol. 1999 Nov;31(8):685-7.
引用本文的文献
1
Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine.药物流行病学研究在解决药物警戒问题中的作用：以使用美沙拉嗪的溃疡性结肠炎患者胰腺炎风险为例
Eur J Clin Pharmacol. 2014 Jun;70(6):709-17. doi: 10.1007/s00228-014-1660-7. Epub 2014 Mar 11.
2
Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine.维持溃疡性结肠炎缓解——每日一次缓释美沙拉嗪的作用
Drug Des Devel Ther. 2011 Feb 27;5:111-6. doi: 10.2147/DDDT.S5392.
3
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.美沙拉嗪颗粒每日一次与每日三次治疗活动期溃疡性结肠炎的疗效比较：一项双盲、双模拟、随机、非劣效性试验
Gut. 2009 Feb;58(2):233-40. doi: 10.1136/gut.2008.154302. Epub 2008 Oct 2.
4
Advances in colonic drug delivery.结肠给药的进展。
Drugs. 2005;65(14):1991-2007. doi: 10.2165/00003495-200565140-00006.
5
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.对于广泛性轻度/中度活动性溃疡性结肠炎患者，口服与灌肠联合使用颇得斯安（美沙拉嗪）治疗优于单纯口服治疗：一项随机、双盲、安慰剂对照研究。
Gut. 2005 Jul;54(7):960-5. doi: 10.1136/gut.2004.060103.
6
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma.5-氨基水杨酸的肠道抗炎作用依赖于过氧化物酶体增殖物激活受体γ。
J Exp Med. 2005 Apr 18;201(8):1205-15. doi: 10.1084/jem.20041948. Epub 2005 Apr 11.
7
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.使用益生菌大肠杆菌Nissle 1917维持溃疡性结肠炎缓解的效果与使用标准美沙拉嗪相当。
Gut. 2004 Nov;53(11):1617-23. doi: 10.1136/gut.2003.037747.
8
No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases.5-氨基水杨酸无剂量依赖性肾小管毒性：一项针对炎症性肠病患者的前瞻性研究。
Int J Colorectal Dis. 2003 Sep;18(5):406-12. doi: 10.1007/s00384-002-0467-7. Epub 2003 Feb 8.
9
Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.5-氨基水杨酸（5-ASA）在炎症性肠病治疗中的作用：一项系统评价。
Dig Dis Sci. 2002 Mar;47(3):471-88. doi: 10.1023/a:1017987229718.
10
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.低剂量巴柳氮（每日两次，每次1.5克）和美沙拉嗪（每日三次，每次0.5克）可维持溃疡性结肠炎的缓解，但高剂量巴柳氮（每日两次，每次3.0克）在预防复发方面更具优势。
Gut. 2001 Dec;49(6):783-9. doi: 10.1136/gut.49.6.783.
本文引用的文献
1
A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis.柳氮磺胺吡啶在慢性溃疡性结肠炎中的应用批判性分析。
Ann Intern Med. 1959 Nov;51:879-89. doi: 10.7326/0003-4819-51-5-879.
2
CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.柳氮磺胺吡啶治疗溃疡性结肠炎的对照试验
Gut. 1964 Oct;5(5):437-42. doi: 10.1136/gut.5.5.437.
3
Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.柳氮磺胺吡啶和水杨酸偶氮磺胺嘧啶治疗溃疡性结肠炎
Lancet. 1962 May 26;1(7239):1094-6. doi: 10.1016/s0140-6736(62)92080-9.
4
Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.在治疗急性溃疡性结肠炎方面，巴柳氮比美沙拉嗪更有效且耐受性更好。算盘研究组。
Gastroenterology. 1998 Jan;114(1):15-22. doi: 10.1016/s0016-5085(98)70627-4.
5
A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.口服美沙拉嗪与直肠用美沙拉嗪及联合治疗远端溃疡性结肠炎的双盲对照研究
Am J Gastroenterol. 1997 Oct;92(10):1867-71.
6
Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.溃疡性结肠炎中直肠用皮质类固醇与替代疗法的比较：一项荟萃分析。
Gut. 1997 Jun;40(6):775-81. doi: 10.1136/gut.40.6.775.
7
Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.接受氨基水杨酸盐治疗的炎症性肠病患者的肾小管功能障碍
Gut. 1997 Jun;40(6):761-6. doi: 10.1136/gut.40.6.761.
8
9
Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group.1.5克与3.0克口服缓释美沙拉嗪（颇得斯安）用于溃疡性结肠炎维持治疗的疗效与安全性比较。荷兰颇得斯安研究组
Eur J Gastroenterol Hepatol. 1995 Nov;7(11):1025-30. doi: 10.1097/00042737-199511000-00003.
10
Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis.高剂量5-氨基水杨酸灌肠剂间歇性治疗可维持溃疡性直肠炎和直肠乙状结肠炎的缓解。
Dis Colon Rectum. 1994 Jan;37(1):58-62. doi: 10.1007/BF02047216.
Zotero 插件